Shuttle Pharmaceuticals HoldingsSHPH +6.35%24 Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus rates SHPH with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 505 Drug Manufacturers companies, Shuttle Pharmaceuticals Holdings ranks worse than 198019.6% on this metric.
SHPH's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.14 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Shuttle Pharmaceuticals Holdings Forward Dividend Yield % Related Terms
SHPH vs PRFX, CBIH, UPC: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shuttle Pharmaceuticals Holdings Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Shuttle Pharmaceuticals Holdings's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Shuttle Pharmaceuticals Holdings (SHPH) has a Forward Dividend Yield % of 0.00% as of Jun. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #999999 out of 505 companies in the Drug Manufacturers industry.
Is Shuttle Pharmaceuticals Holdings' Forward Dividend Yield % too high?
Shuttle Pharmaceuticals Holdings' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Shuttle Pharmaceuticals Holdings ranks #999999 out of 505 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shuttle Pharmaceuticals Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Shuttle Pharmaceuticals Holdings' Forward Dividend Yield % compare to PRFX and CBIH?
According to the Drug Manufacturers industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #999999 out of 505 companies for Forward Dividend Yield %. This places Shuttle Pharmaceuticals Holdings in the lower half of its industry. The industry median Forward Dividend Yield % is 2.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.14, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shuttle Pharmaceuticals Holdings's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shuttle Pharmaceuticals Holdings stock overvalued right now?
Shuttle Pharmaceuticals Holdings (SHPH) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Shuttle Pharmaceuticals Holdings' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Shuttle Pharmaceuticals Holdings (SHPH), the current Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shuttle Pharmaceuticals Holdings Business Description
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
24GF Score
Get the complete analysis for SHPH
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPH has been successfully added to your 